Motor nerve conduction (MNC) from proximal and distal points of the median and ulnar nerves was examined in 14 patients receiving a total of 29 i.v. regional anaesthetics (IRA) with bupivacaine hydrochloride in doses ranging from 100 to 300 mg. Conduction was tested during and following vascular obstruction, until MNC returned to pre-IRA value. After 20 min of obstruction, MNC was unobtainable in most patients, an effect which was dose-related. The action of bupivacaine on MNC persisted for up to 3 h after cuff release, depending on the dose, and paralleled voluntary movements. MNC block began at the proximal point of both nerves, the median nerve being affected earlier. Based on the clinical and electrical findings, bupivacaine 200 mg proved to be the optimum dose for producing safe and prolonged IRA.
Local anaesthetic agents block nerve conduction, as demonstrated by a progressive decrease in amplitude of the evoked response, and a delay of response and slower velocity of conduction. The effect, which is reversible, is more marked in sensory than in motor fibres (Mazzarella, Bravaccio and Memoli, 1966; de Jong and Nace, 1968) . I.v. regional anaesthesia (IRA) with lignocaine hydrochloride results in the same phenomena, but only for as long as the sphygmomanometer cuff remains inflated (Shanks and McLeod, 1970) .
The analgesic effect of bupivacaine hydrochloride, on the other hand, may persist for a variable time after cuff release (Watson, Brown and Reich, 1970; Evans et al., 1974; Magora et al., 1978) . This characteristic action of the drug has been attributed to its strong binding power to the nerve lipoproteins (Tucker and Boas, 1971) .
Motor nerve conduction (MNC) studies were carried out during and after release of vascular obstruction, to assess the effects of IRA with bupivacaine. The results were compared with the values of MNC before IRA, and correlated with clinical evidence of analgesia and motor weakness. 
PATIENTS AND METHODS
Fourteen patients were studied: seven suffered from shoulder-hand syndrome, three from causalgia, two from sympathetic reflex dystrophy, one from painful spasticity, and in one patient IRA was administered to evaluate release of elbow and wrist flexion contracture. The nature of the treatment and examination was explained to the patient and informed consent was obtained in all instances.
Three patients received IRA with 100 mg of bupivacaine (40 ml, 0.25%), five with 150 mg (60 ml, 0.25%), 14 with 200 mg (40 ml, 0.50%) and seven with 300 mg (60 ml, 0.50%). In nine patients, IRA was induced more than once.
Vascular obstruction was maintained for 20 min, after which the cuff was released in an on-off manner, repeated four or five times, each deflation lasting 10 s and each re-inflation continuing for 50 s. The patient was under constant medical observation throughout the procedure.
MNC was assessed for the ulnar and median nerves, the signals being picked up by coaxial needle electrodes placed in the abductor digiti minimi and opponens pollicis muscles, respectively. Supramaximal stimuli of 0.5 ms duration were given at the proximal (elbow) and distal (wrist) points of the nerves, both these points being located below the tourniquet. Amplitude, duration and delay of the evoked response were measured and recorded. MNC was examined before administration of IRA, at intervals of 5 min during the 20-min vascular obstruction, and every 5-15 min after cuff release until the measurements had returned to the values recorded before IRA. For purposes of comparison, four of the patients received lignocaine 40 ml (0.5% solution) also, while vascular obstruction was maintained for 40 min.
Concomitant with the MNC assessments, voluntary finger movements, analgesia (pin-prick) and touch sensation including the subjective feeling of numbness, were assessed. Whenever the clinical effects persisted for more than 1 h after the release of vascular obstruction, MNC was reexamined at 30-min intervals until the value had returned to normal.
RESULTS
Since the smallest degree of variability occurred in the delay of the evoked response while, at the same time, it reflected the changes encountered in the other indices, the tabulated results relate to the value of delay (latency) only.
The tables include the average latencies in the respective groups of patients before, at pre-set times during, and for various intervals after vascular obstruction. In parentheses are the numbers of patients in whom no response could be elicited (minus signs), or in whom the delay returned to the pre-IRA value (n-sign). 9.9(-l)t 10.4 (-1) 8.8 (-3) (-5) 9.0 (-3) 9.5 (-2) 9.4(-l) 9.5 9.3 (n= 1) 9.0 (n = 2) 9.7(-l)(n = 9.5(-l)(« = 8.3 (-!)(« = 7.9 (n = 2) 7.9 (n = 2) (« = 5)
IRA with bupivacaine 100 mg {table I, fig. 1 ). During vascular obstruction there was a prolonged delay of conduction in the median and ulnar nerves, from both the proximal and distal points of stimulation. The delay returned to pre-IRA values within 45 min of tourniquet release. The evoked response did not disappear in any of the three patients.
IRA with bupivacaine 150 mg (table II; fig. 2 ). An increase in delay was apparent within the first 5 min, being more pronounced at the proximal point of both nerves. At 20 min of obstruction, there was no evoked response from the proximal point of the median nerve in any of the five patients, while in three no response was elicited from the distal point. In the ulnar nerve, conduction was completely blocked proximally in two patients and distally in one. When a response could be obtained, the delay was markedly longer. Upon release of vascular obstruction, the effects from the proximal point of the median nerve were more prolonged. Thirty minutes later, only a diminished response could be elicited in all the patients; at 2 h, all had returned to normal. Similar phenomena, but to a lesser degree, were noted from the distal point of the median nerve with a return to normal at 1 h after release of the tourniquet.
In the ulnar nerve, the effects were less marked: at 5 min following cuff release, the delay from the proximal point had returned to normal in one, and from the distal point in two patients; within 1 h all values had returned to normal. III, fig. 3 ). The results were similar to those obtained for IRA with bupivacaine 150 mg; again, the effects were more marked in the median nerve and from the proximal points of both nerves. The delay values returned to normal within 1-2 h of cuff release.
IRA with bupivaccrine 200 mg (table
IRA vnth bupivacaine 300 mg (table IV, fig. 4 ). In all seven patients, the evoked response became ,. unobtainable from the proximal point of the median nerve within 5 min of vascular obstruction, and from the ulnar nerve within 15 min. From the distal point of the median nerve no response occurred after 20 min of obstruction in any of the patients; in six subjects, the response (from the distal point) from the ulnar nerve was absent. In all patients, and from both nerves, this quantity of bupivacaine (300 mg) resulted in effects that were more prolonged than at smaller doses. The delay in nerve conduction from the distal point returned to normal 2 h after cuff release (slightly longer in the ulnar nerve), and from the proximal point of stimulation it reverted to normal within 3 h in the median and 4.5 h in the ulnar nerve. In the four patients who received IRA with lignocaine 200 mg, the effects upon MNC were similar to those of bupivacaine but of a much shorter duration. The delay returned to pre-IRA values within 20-30 min following release of the vascular obstruction.
On clinical assessment, the muscle strength followed the findings with MNC: movement reappeared after nerve conduction had become obtainable again; prolonged delay in conduction was accompanied by severe muscle weakness, and muscle power returned to normal within 1 h after MNC had returned to pre-IRA values. Partial sensory loss persisted in all patients for longer periods of time, and there was a subjective feeling of numbness for up to 14 h.
Except for transient drowsiness in two patients, there were no signs of toxicity (such as uncontrolled movement, arrhythmia, significant changes in arterial pressure) in any instance.
DISCUSSION
The clinical and electrical effects of i.v. regional anaesthesia with bupivacaine may continue for various periods of time after release of vascular obstruction. These effects are characterized by persistent numbness, analgesia, weakness and partial or complete block of motor nerve conduction.
The block is demonstrated by the disappearance or prolonged latency and low amplitude of the evoked response (de Jong and Nace, 1968; Shanks and McLeod, 1970) .
IRA with lignocaine resulted in blockage of conduction during vascular obstruction, which started to return to normal within 5 min of cuff release and reached pre-IRA values within 20 min. Under bupivacaine anaesthesia, the nerve conduction block persisted for up to 3 h, with a slow and general return to normal. Lignocaine effects on nerve conduction similar to those of bupivacaine were reported by Shanks and McLeod (1970) . Furthermore, the influence of bupivacaine cannot be attributed to the limb ischaemia per se, mainly because the period of vascular obstruction during IRA with lignocaine was 40 min as compared with 20 min when using the former drug. Shanks and McLeod (1970) and Hainaut and Golde (1976) have demonstrated that the electrical changes in nerve conduction caused by 20-min limb ischaemia disappear within a few minutes of tourniquet release. The observations on bupivacaine and MNC are strengthened by the fact that IRA with both bupivacaine and lignocaine was carried out on the same patients.
Bupivacaine began to exert its activity within 5 min of cuff inflation, irrespective of dose; the effect became maximal at 15-20 min, and persisted after release of obstruction. Because the maximum effects seem to occur at 20 min, and analgesia persists after cuff release, the cuff may be deflated after this period of time if it is thought desirable for other reasons.
The block of nerve conduction caused by IRA with bupivacaine was dose-related both during and after vascular obstruction. The lowest intensity of effect was noted using lOOmg, while maximum blockage of MNC occurred with doses of 300 mg of bupivacaine.
Comparison of conduction in the two nerves examined shows that the effects were more pronounced in the median nerve with small doses of bupivacaine, while at greater doses, the block and delay of conduction were similar in both nerves. The earlier effect upon the median nerve may be explained by the larger venous channels surrounding the nerves in the anteromedial compartment of the elbow (Raj et al., 1972) .
The block of conduction in both nerves appeared first at the proximal point (elbow) and spread centrifugally and the intensity of the effect was also more pronounced at this point. This indicates that the block originates in the nerve trunk, as already demonstrated in IRA with lignocaine (Sorbie and Chacha, 1965; Fleming et al., 1966; Shanks and McLeod, 1970) . Although neither the myoneural junction nor the terminal fibres of the nerves were examined, it may be that they were affected to some extent also. The return to normal nerve conduction started distally (wrist).
Restoration of normal clinical and electrical function commenced 5-15 min following cuff release, but analgesia, weakness and abnormal MNC persisted for at least 20 min with injection of bupivacaine 100 mg and up to 240 min with 200 and 300 mg of the drug. In general, the muscle weakness paralleled MNC values, while sensory loss slightly preceded the slowing of conduction and continued in a patchy form for 1-3 h after MNC had returned to normal. A subjective feeling of numbness and clumsiness was present in 19 of the 29 IRA administered which continued for 6-20 h subsequent to cuff release in spite of a normal MNC. This manifestation was more pronounced with the greater doses of bupivacaine. Analgesia and weakness were present during IRA, even when an evoked response was still obtainable. In these instances, however, the evoked response was prolonged and the amplitude remained less than 1 mV. This discrepancy between MNC and clinical analgesia is explained by the fact that nerve conduction demonstrates the state of nerve fibres with large diameters, while painful stimuli are transmitted by fibres with small diameter. This mode of action was proved by Rosenfalck (1969) , who showed that a slowing of conduction to half the normal value was not accompanied by an impairment of touch sensation, by Collins, Nulsen and Clark (1960) who demonstrated that painful stimulation was not perceived although conduction of alpha, beta and gamma fibres remained normal, and by Wencker, Nolte and Fruhstorfer (1975) who found normal electrical activity before the muscle power had recovered completely.
MNC has proved to be a reliable indicator of the duration of the effects of IRA upon voluntary movements. Although marked individual variations in intensity and extent of both clinical and electrical effects were noted, it was demonstrated objectively that bupivacaine had a prolonged effect after cuff release in all patients (Magora et al., 1980) . As the clinical effects, especially sensory, were similar with doses of bupivacaine 200 mg and 300 mg and the MNC was similar at doses of bupivacaine 150 mg and 200 mg, it is recommended that for analgesic-therapeutic purposes IRA be carried out with bupivacaine 200 mg. This quantity permits continuation of surgery or intensive physiotherapy under conditions of analgesia after the release of the tourniquet. CONDUCTION 
SUMAR1O
Se cxamino la conduccion del nervio motor desde puntos proximos y distantes de los nervios mediano y cubital en 14 pacientes que recibieron un total de 29 anestesicos intravenosos locales usando hidrocloruro de bupivacaina en dosis que oscilaron entre 100 y 300 mg. La conduccion se observo durante la obstruction vascular, y despues de csta, hasta que aquella volvio a su valor previo a la administration de los anestesicos. La conduccion del nervio motor no se consiguio despues de una espera de 20 min en la mayoria de los pacientes, efecto que va en funcion de la dosis. La influencia de la bupivacaina persistio en la conduccion del nervio motor hasta un maximo de 3 h despues de soltar el yugo, en funcion de la dosis, y de los movimientos voluntarios en paralelo. El bloqueo de la conduccion del nervio motor comenzo en los puntos proximos de ambos nervios, siendo afectado antes el nervio mediano. En base a los resultados clinicos y electricos, 200 mg de bupivacaina demostraron ser la dosis optima para producir seguros y prolongados anestesicos intravenosos locales.
